TrialAmerican journal of hematology2018

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Tadeusz Robak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.